Higher pre-treatment levels of IL-6 predict a poorer response to antidepressants (Lanquillon et al., 2000; Maes et al., 1997) and antipsychotics (Lin et al., 1998; Mondelli et al., 2015) in patients with depression and schizophrenia, respectively. This evidence concerns the gene IL6 and depressive symptom measurement.